

Mark C Kelley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4879406/publications.pdf>

Version: 2024-02-01

19
papers

1,569
citations

567281

15
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

2517
citing authors

#	ARTICLE	IF	CITATIONS
1	Metastatic Melanoma Patientâ€œDerived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 3803-3818.	7.0	21
2	Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. <i>Nature Nanotechnology</i> , 2019, 14, 269-278.	31.5	406
3	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. <i>Cancer Immunology Research</i> , 2019, 7, 86-99.	3.4	27
4	<scp>BRAF</scp> and <scp>MEK</scp> inhibitor therapy eliminates Nestinâ€œexpressing melanoma cells in human tumors. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 708-719.	3.3	9
5	Evaluating feasibility of an automated 3-dimensional scanner using Raman spectroscopy for intraoperative breast margin assessment. <i>Scientific Reports</i> , 2017, 7, 13548.	3.3	45
6	A phase <scp>II</scp> trial of erlotinib and bevacizumab for patients with metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 101-103.	3.3	11
7	Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv406.	6.3	61
8	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. <i>Immunotherapy</i> , 2015, 7, 611-619.	2.0	141
9	Preliminary Results from a Prospective Trial of Preoperative Combined BRAF and MEK-Targeted Therapy in Advanced BRAF Mutation-Positive Melanoma. <i>Journal of the American College of Surgeons</i> , 2015, 220, 581-593e1.	0.5	26
10	Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. <i>Cancer Research</i> , 2015, 75, 181-193.	0.9	76
11	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015, 6, 22348-22360.	1.8	12
12	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 373-377.	3.4	100
13	Long-termâ€œcure after complete resection and adjuvant immunotherapy for distant melanoma metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8534-8534.	1.6	1
14	Development of a spatially offset Raman spectroscopy probe for breast tumor surgical margin evaluation. <i>Journal of Biomedical Optics</i> , 2011, 16, 077006.	2.6	162
15	Autofluorescence and diffuse reflectance spectroscopy and spectral imaging for breast surgical margin analysis. <i>Lasers in Surgery and Medicine</i> , 2010, 42, 15-23.	2.1	92
16	Comparison of autofluorescence, diffuse reflectance, and Raman spectroscopy for breast tissue discrimination. <i>Journal of Biomedical Optics</i> , 2008, 13, 054009.	2.6	68
17	Accuracy of Intraoperative Gross Examination of Surgical Margin Status in Women Undergoing Partial Mastectomy for Breast Malignancy. <i>American Surgeon</i> , 2005, 71, 22-28.	0.8	120
18	Accuracy of intraoperative gross examination of surgical margin status in women undergoing partial mastectomy for breast malignancy. <i>American Surgeon</i> , 2005, 71, 22-7; discussion 27-8.	0.8	92

#	ARTICLE	IF	CITATIONS
19	Lymphatic mapping and sentinel lymphadenectomy for breast cancer. American Journal of Surgery, 2004, 188, 49-61.	1.8	99